Eli Lilly Partners with Ro to Offer Affordable Zepbound via Telehealth

Ro, a direct-to-consumer health-care startup, has partnered with Eli Lilly to offer more affordable single-dose vials of the weight loss drug Zepbound. This integration allows patients to receive a diagnosis, prescription, and home delivery of Zepbound through Ro's platform, streamlining access to the drug. The vials, available via LillyDirect, are a cash-pay product and cost significantly less than the autoinjector form, making them more accessible to uninsured patients. This move aims to expand access to branded Zepbound and counter the rise of cheaper compounded versions.